Brind.
  1. AxoGen is seeking BLA approval for its Avance Nerve Graft, and the FDA extended the review date for the application.

AxoGen, a Florida-based company, announced on July 3rd that it invested in Avance and presented at a Goldman Sachs conference.

1 report, 0 independent Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

AxoGen, a Florida-based company, announced on July 3rd that it invested in Avance and presented at a Goldman Sachs conference.

Who's involved

What this event is mainly about
AxoGenAvance

Keep exploring

Part of

AxoGen is seeking BLA approval for its Avance Nerve Graft, and the FDA extended the review date for the application. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Unknown outlet